What is ParaPRO?
ParaPRO operates at the intersection of public health and advanced pharmacology, focusing on the development of targeted therapies for common parasitic infestations. The company is best known for its flagship product, Natroba, a topical suspension that has become a standard of care for head lice treatment. By leveraging spinosad, a naturally derived anti-parasitic agent, ParaPRO addresses the growing clinical challenge of treatment resistance. This focus on pediatric and family health solutions positions the company as a high-authority player in the dermatology and infectious disease landscape, effectively bridging the gap between traditional treatments and modern, resistance-proof therapeutic alternatives.
How much funding has ParaPRO raised?
ParaPRO has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in ParaPRO
PPP
Public-Private Partnership
What's next for ParaPRO?
Following this late-stage financing, ParaPRO is well-positioned to scale its commercial operations and potentially expand its therapeutic pipeline. The strategic allocation of this capital will likely focus on deepening market penetration for Natroba while exploring new indications for its proprietary spinosad-based technology. As the company transitions into this next phase of growth, stakeholders will be monitoring its ability to maintain its competitive edge against generic alternatives and its capacity to innovate within the niche but essential public health market. The firm's commitment to pediatric health remains a core pillar of its long-term value proposition.
See full ParaPRO company page
